METABOLICALLY ASSOCIATED FATTY LIVER DISEASE AND THYROID HYPOFUNCTION: GENETIC ASPECTS

Metabolically associated fatty liver disease is the most common chronic liver disease, characterized by pathological changes in liver cells, with hepatic fat accumulation and impaired metabolism.

Thyroid hypofunction is a common endocrine disorder characterized by a deficiency of thyroid hormones, which negatively affects the body’s overall metabolic balance.

Studies have shown that genetic predisposition factors, hereditary mutations, polymorphisms, and epigenetic mechanisms play an important role in the development of thyroid hypofunction and hepatic steatosis. Molecular genetic investigations, including analyses of gene expression changes and nucleotide sequence variations, are of fundamental importance. Based on genetic markers, it becomes possible to assess patients’ disease risk and to develop personalized diagnostic and therapeutic strategies. It is also important to substantiate the relationship between the clinical manifestations of metabolically associated fatty liver disease and thyroid hypofunction and their genetic determinants. The results of genetic research play a crucial role in disease prevention, early diagnosis, and effective treatment. In modern medicine, it is necessary to propose practical recommendations aimed at reducing disease progression and improving patients’ quality of life through the implementation of genetic counseling, molecular diagnostics, and preventive strategies.

Studying the genetic basis of these two conditions is important not only at the research level but also in clinical practice, as it contributes to the development of personalized medicine and modern therapeutic approaches.